EUCTR2009-012607-26-DE进行中（未招募）不适用
MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers - MIMEB
niversity of Cologne0 个研究点开始时间: 2009年9月8日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with histologically or cytologically proven non-squamous NSCLC stage IIIB with pleural effusion or stage IV
- •= 18 years of age
- •Performance status ECOG 0-2
- •Estimated life expectancy of at least 12 weeks
- •Subjects with at least one measurable (CT or MRI) lesion according to RECIST
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •-Hemoglobin = 9.0 g/dL
- •-Absolute neutrophil count (ANC) = 1,500 /mm3
- •-Platelet count = 100 000/µL
- •-Total bilirubin = 2 x ULN
- •-ALT, AST and alkaline phosphatase (AP) = 2,5 x ULN
- •-PT-INR/PTT < 1.5 x ULN
- •-Creatinine clearance (CrCl) = 60 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection
- •Written informed consent (after adequate explanation of the trial) to participate in the trial and to adhere to trial procedures, as well as consenting to data protection procedures
- •No clinical or radiological sign of interstitial lung disease, no interstitial lung disease in the past
- •Patients must be able to take oral medication
- •In case of female patients with childbearing potential:
- •-negative serum or urine HCG in women with childbearing potential
- •-effective method of contraception (Pearl-Index not greater than 1%)
- •-at least 12 months after last menstruation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient has received prior chemotherapeutic regimens for advanced disease. Prior chemotherapy given as neoadjuvant or adjuvant therapy for early stage disease, completed at least 12 months prior to diagnosis of advanced stage disease, will not be considered as exclusion criterion.
- •Patient has received prior EGFR-targeted therapy
- •Squamous-cell carcinoma (SCC) histology, SCLC histology or mixed histology
- •Evidence of tumor invading or abutting major blood vessels
- •Patient has signs or symptoms of acute infection requiring systemic therapy (acute or within the last 14 days)
- •Uncontrolled diabetes mellitus with HbA1c > 7,5% or elevated blood glucose levels levels of > 200 mg/dL
- •History of uncontrolled heart disease (congestive heart failure > NYHA class 2; active Coronary Arterial Disease (CAD), (MI more than 6 months prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (except, when controlled by beta blockers or digoxin) and/or uncontrolled hypertension (> 150/100 mmHg)
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of erlotinib and (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection, total parenteral nutrition with lipids)
- •History of HIV infection or previously sero-positive for the virus
- •History of Hepatitis B or/and C or previously sero-positive for the Hepatitis B or/and C virus
- •Patients with seizure disorder requiring CYP3A4-inducing anti-epileptics
- •History of organ allograft
- •Patients with evidence or history of bleeding diathesis
- •History of thrombotic disorders within the last 6 months prior to enrolment
- •Fine needle biopsy or open biopsy within 1 week prior inclusion
- •Clinically symptomatic leptomeningeal or brain metastases (patients with clinically stable brain metastases may be enrolled)
- •Impaired wound healing, non-healing wounds, ulcers, fractures or any condition that provokes uncontrolled bleeding
- •Preexisting neuropathia ? grade 2
- •History of grade =2 hemoptysis (bright red blood of at least 2.5 ml)
- •Patients undergoing renal dialysis
- •Past or current history of cancer other than the entry diagnosis EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
- •Any person being in an institution on assignment of the respective authority
- •Urine protein qualitative value of > 30 in urinalysis or > +1 in proteinuria testing by dipstick
- •Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
- •Concomitant or intented anticoagulation therapy
- •Planned surgical or dental invasive intervention (e.g. tooth extraction, planned surgeries) during the course of the study
- •Any serious medical condition with organ impairment
- •Hypersensitivity to bevacizumab or erlotinib or any of their ingredients
- •Major surgery or significant traumatic injury within the last 4 weeks before inclusion
- •Parallel participation in another clinical trial or participation in another clinical trial within the last 30 days or 7 half-life's, whatever is of longer duration, prior study start
- •Pregnancy, breast feeding
- •Claustrophobia
- •Known allergic reaction to Gadolinium
- •Heart pacemaker
- •Ferromagnetic and electronic implants in special locations (e. g. cerebral)
研究者
相似试验
招募中
不适用
High-sensitivity imaging of erlotinib in resected non-small-cell lung cancerJPRN-UMIN000009745Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine Shimane University Faculty of Medicine1
已完成
1 期
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)Carcinoma, Non-small Cell LungNCT00729742Merck Sharp & Dohme LLC49
尚未招募
不适用
Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma; a feasibility study in patients who do not show response on bevacizumab therapy.10017990colon cancerNL-OMON31048niversitair Medisch Centrum Groningen6
已完成
不适用
Molecular imaging with radiolabeled bevacizumab in metastatic colon carcinoma. A feasibility study in patients who do show response on bevacizumab therapy10017990colon cancerNL-OMON30912niversitair Medisch Centrum Groningen6
已完成
不适用
Everolimage. 89Zr-bevacizumab PET imaging in patients with Renal Cell Carcinoma treated with everolimus; a pilot study.kidney cancer1003836310038430renal cell carcinomaNL-OMON36512niversitair Medisch Centrum Groningen14